新型抗体类药物在急性B淋巴细胞白血病中的治疗进展

摘要/Abstract

中图分类号:

R733.71

任佳逸, 糜坚青. 新型抗体类药物在急性B淋巴细胞白血病中的治疗进展[J]. 内科理论与实践, 2022, 17(06): 463-467.

REN Jiayi, MI Jianqing. Progress of novel antibody-like drugs in treatment of acute B lymphoblastic leukemia[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(06): 463-467.

参考文献23

[1]	Lanza F, Maffini E, Rondoni M, et al. CD22 expression in B-cell acute lymphoblastic leukemia[J]. Cancers (Basel), 2020, 12(2): 303. doi:10.3390/cancers12020303 URL
[2]	DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies[J]. Blood, 2004, 103(5): 1807-1814. doi:10.1182/blood-2003-07-2466pmid:14615373
[3]	Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia[J]. Lancet Oncol, 2012, 13(4): 403-411. doi:10.1016/S1470-2045(11)70386-2pmid:22357140
[4]	Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia[J]. Cancer, 2019, 125(14): 2474-2487. doi:10.1002/cncr.32116pmid:30920645
[5]	Short NJ, Kantarjian H, Ravandi F, et al. Updated results from a phase Ⅱstudy of mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl 1: 3400.
[6]	Chevallier P, Leguay T, Doubek M, et al. Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy provides very good outcome in older patients with newly diagnosed CD22⁺Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl 1: 511.
[7]	Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cellsin vitro[J]. Leukemia, 2000, 14(5): 853-858. pmid:10803517
[8]	Schindler J, Gajavelli S, Ravandi F, et al. A phase Ⅰ study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia[J]. Br J Haematol, 2011, 154(4): 471-476. doi:10.1111/j.1365-2141.2011.08762.x URL
[9]	Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity[J]. Clin Cancer Res, 2005, 11(4): 1545-1550. doi:10.1158/1078-0432.CCR-04-1939pmid:15746059
[11]	Shah NN, Bhojwani D, August K, et al. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2020, 67(5): e28112.
[12]	Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma[J]. Blood, 2009, 24(13):2721-2729.
[13]	Tilly H, Morschhauser F, Bartlett NL, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study[J]. Lancet Oncol, 2019, 20(7): 998-1010. doi:S1470-2045(19)30091-9pmid:31101489
[14]	Jones L, McCalmont H, Evans K, et al. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin(SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts[J]. Pediatr Blood Cancer, 2019, 66(8): e27765.
[15]	Kantarjian HM, Lioure B, Kim SK, et al. A phase Ⅱ study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2016, 16(3): 139-145. doi:10.1016/j.clml.2015.12.004pmid:26775883
[16]	Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab[J]. Blood, 2012, 119(26): 6226-6233. doi:10.1182/blood-2012-01-400515pmid:22592608
[17]	Topp MS, Göckbuget N, Stein AS. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia[J]. Lancet Oncol, 2015, 16(1): 57-66. doi:10.1016/S1470-2045(14)71170-2pmid:25524800
[18]	Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomabversuschemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. doi:10.1056/NEJMoa1609783 URL
[19]	Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults[J]. N Engl J Med, 2020, 383(17): 1613-1623. doi:10.1056/NEJMoa2016272 URL
[20]	Gökbuget N, Stoltefuß A, Topp M, et al. Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with B-precursor adult lymphoblastic leukemia(ALL)[J]. Blood, 2021, 138 Suppl 1: 3399.
[21]	Nicholas J, Kantarjian H, Ravandi F, et al. Updated results from a phase Ⅱ study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed philadelphia chromosome-negative B-cell acute lymphoblastic leukemia[J]. Blood, 2021, 138 Suppl: 1233.
[22]	Abuasab T, Rowe J, Tvito A. Emerging monoclonal antibody therapy for the treatment of acute lymphoblastic leukemia[J]. Biologics, 2021, 15: 419-431. doi:10.2147/BTT.S290294pmid:34703207
[23]	Cremasco F, Menietti E, Speziale D, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model[J]. PLoS One, 2021, 16(1): e0241091. doi:10.1371/journal.pone.0241091 URL

[1]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜.肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[2]	于颖彦.免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.
[3]	王思颖，郑幸玲，覃文新.癌症患者能否长期生存？[J]. 开云网页登录学报, 2021, 55(Sup.1): 49-50.
[4]	宗春燕，沈键锋.免疫治疗能否治愈肿瘤？[J]. 开云网页登录学报, 2021, 55(Sup.1): 53-54.
[5]	杨哲宇, 陆骋豪(综述), 蔡伟(审校).浆细胞样树突状细胞与肿瘤免疫研究的新进展[J]. 外科理论与实践, 2021, 26(6): 568-572.
[6]	罗雅方, 徐倩玥, 余红.尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021, 20(06): 592-595.
[7]	苏长青.从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[8]	周艺, 杨莉.粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[9]	钱梨寒, 沈柏用.局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.
[10]	郝杰, 楚小鸽, 李超, 巴音才次克, 董光苹, 刘占云, 刘振宇, 王静懿, 李良群, 孙海波, 陈瑜, 陈秋生, 孙慧平, 糜坚青, 王瑾,.培门冬酶治疗成人Ph/BCR-ABL1阴性急性淋巴细胞白血病药物活性与疗效[J]. 内科理论与实践, 2019, 14(06): 355-360.
[11]	田明明, 吴涛, 薛锋, 汉英, 张丽萍, 王存邦, 白海.Ph（+）急性淋巴细胞白血病伴骨髓坏死一例[J]. 诊断学理论与实践, 2019, 18(05): 585-587.
[12]	罗清琼, 陈福祥.肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393.
[13]	程石, 赵修浩.胆囊癌治疗的若干热点问题[J]. 外科理论与实践, 2019, 24(02): 100-104.
[14]	王晓斐, 高蓓莉.肺癌免疫治疗标志物研究进展认识[J]. 诊断学理论与实践, 2018, 17(05): 494-498.
[15]	汤葳, 周俊,.充分发挥特异性免疫治疗在过敏性哮喘中的应用[J]. 内科理论与实践, 2018, 13(03): 138-141.

新型抗体类药物在急性B淋巴细胞白血病中的治疗进展

Progress of novel antibody-like drugs in treatment of acute B lymphoblastic leukemia

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献23

相关文章15

编辑推荐

Metrics

本文评价